In previous studies, researchers identified a class of compounds called aminoarylthiazoles (AATs) that potentially correct the F508del-CFTR protein. Now they want to identify new F508del correctors belonging to the family of aminoarylthiazoles (AATs) or VX-809 hybrid derivatives. The study will be carried out by computational techniques able to identify pharmacophore and pharmacokinetic units of the molecules. Well-defined descriptors selected by QSAR (Quantitative Structure–Activity Relationship) will be used as filtering tools guiding for the optimization of the new hybrid series. For the chemical synthesis conventional methods of organic synthesis will be used; all the molecules will be purified with liquid chromatography (HPLC) and characterized by mass spectrometry analysis. Finally, their activity to recover the mutant CFTR will be tested by functional and biochemical assays. The whole project may achieve a reliable computational model to study new CFTR drugs.